Literature DB >> 21924460

Expression profile of E-cadherin and N-cadherin in urothelial carcinoma of the upper urinary tract is associated with disease recurrence in patients undergoing nephroureterectomy.

Mototsugu Muramaki1, Hideaki Miyake, Tomoaki Terakawa, Yuji Kusuda, Masato Fujisawa.   

Abstract

OBJECTIVE: To investigate the impact of the expression profile of E-cadherin and N-cadherin in urothelial carcinoma of the upper urinary tract (UC-UUT) on the probability of intra- and extravesical disease recurrence in patients undergoing nephroureterectomy.
METHODS: This study included 59 consecutive patients diagnosed as having clinically localized UC-UUT who underwent nephroureterectomy. Expression levels of E-cadherin and N-cadherin in resected specimens from these patients were measured by immunohistochemical staining.
RESULTS: In this series, intra- and extravesical recurrence occurred in 20 (33.9%) and 19 (32.2%) patients, respectively. Both intra- and extravesical recurrence-free survivals significantly favored patients with positive E-cadherin or negative N-cadherin expression compared with those of patients with reduced E-cadherin or positive N-cadherin expression, respectively. Univariate analysis identified pathologic T stage, multifocality, and N-cadherin expression as significant predictors of intravesical recurrence, of which multifocality and N-cadherin expression were independently related to intravesical recurrence-free survival on multivariate analysis. Furthermore, pathologic T stage, grade, lymph node metastasis, E-cadherin expression, and N-cadherin expression were significantly associated with extravesical recurrence-free survival on univariate analysis. Of these significant factors, pathologic T stage, grade, lymph node metastasis, and N-cadherin expression were shown to be independent predictors of extravesical recurrence on multivariate analysis.
CONCLUSION: These findings suggest that expression profiles of E-cadherin and N-cadherin, particularly the gain of N-cadherin rather than loss of E-cadherin expression, in UC-UUT appeared to be significantly associated with disease recurrence after nephroureterectomy.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21924460     DOI: 10.1016/j.urology.2011.07.1388

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  13 in total

1.  Prognostic significance of PD-L1 expression on tumor cells and tumor-infiltrating mononuclear cells in upper tract urothelial carcinoma.

Authors:  Bo Zhang; Wei Yu; Xueru Feng; Zheng Zhao; Yu Fan; Yisen Meng; Shuai Hu; Yun Cui; Qun He; Hong Zhang; Dong Li; Zhisong He; Liqun Zhou; Jie Jin; Wenke Han
Journal:  Med Oncol       Date:  2017-04-13       Impact factor: 3.064

2.  Significance of ureteroscopic biopsy grade in patients with upper tract urothelial carcinoma.

Authors:  Junya Furukawa; Hideaki Miyake; Iori Sakai; Masato Fujisawa
Journal:  Curr Urol       Date:  2012-12-21

3.  Novel variants in MLL confer to bladder cancer recurrence identified by whole-exome sequencing.

Authors:  Song Wu; Zhao Yang; Rui Ye; Dan An; Chong Li; Yitian Wang; Yongqiang Wang; Yi Huang; Huan Liu; Feida Li; Luyun He; Da Sun; Yuan Yu; Qiaoling Li; Peide Huang; Meng Zhang; Xin Zhao; Tengteng Bi; Xuehan Zhuang; Liyan Zhang; Jingxiao Lu; Xiaojuan Sun; Fangjian Zhou; Chunxiao Liu; Guosheng Yang; Yong Hou; Zusen Fan; Zhiming Cai
Journal:  Oncotarget       Date:  2016-01-19

4.  Distinct subcellular localization of E-cadherin between epithelioid angiomyolipoma and triphasic angiomyolipoma: A preliminary case-control study.

Authors:  Xin-Gang Bi; Lei Guo; Xiao-Liang Wang; Qian Wei; Qiang Du; Wen-Hao Jiang; Guang-Yuan Zheng; Hong-Tu Zhang; Jian-Hui Ma; Shan Zheng
Journal:  Oncol Lett       Date:  2017-05-29       Impact factor: 2.967

5.  Prognostic role of expression of N-cadherin in patients with upper tract urothelial carcinoma: a multi-institutional study.

Authors:  Mohammad Abufaraj; Marco Moschini; Francesco Soria; Kilian Gust; Mehmet Özsoy; Romain Mathieu; Morgan Rouprêt; Vitaly Margulis; Jose A Karam; Christopher G Wood; Alberto Briganti; Karim Bensalah; Andrea Haitel; Shahrokh F Shariat
Journal:  World J Urol       Date:  2016-11-09       Impact factor: 4.226

Review 6.  Tissue-based molecular markers in upper tract urothelial carcinoma and their prognostic implications.

Authors:  Ricardo L Favaretto; Stênio C Zequi; Renato A R Oliveira; Thiago Santana; Walter H Costa; Isabela W Cunha; Gustavo C Guimarães
Journal:  Int Braz J Urol       Date:  2018 Jan-Feb       Impact factor: 1.541

7.  Does reduced E-cadherin expression correlate with poor prognosis in patients with upper tract urothelial cell carcinoma?: A systematic review and meta-analysis.

Authors:  Bum Sik Tae; Chang Wook Jeong; Cheol Kwak; Hyeon Hoe Kim; Ja Hyeon Ku
Journal:  Medicine (Baltimore)       Date:  2019-10       Impact factor: 1.889

8.  Loss of N-Cadherin Expression in Tumor Transplants Produced From As+3- and Cd+2-Transformed Human Urothelial (UROtsa) Cell Lines.

Authors:  Elizabeth J Sandquist; Seema Somji; Jane R Dunlevy; Scott H Garrett; Xu Dong Zhou; Andrea Slusser-Nore; Donald A Sens
Journal:  PLoS One       Date:  2016-05-25       Impact factor: 3.240

9.  Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma: a multi-institutional study.

Authors:  Ricardo L Favaretto; Atessa Bahadori; Romain Mathieu; Andrea Haitel; Bernhard Grubmüller; Vitaly Margulis; Jose A Karam; Morgan Rouprêt; Christian Seitz; Pierre I Karakiewicz; Isabela W Cunha; Stenio C Zequi; Christopher G Wood; Alon Z Weizer; Jay D Raman; Mesut Remzi; Nathalie Rioux-Leclercq; Solene Jacquet-Kammerer; Karim Bensalah; Yair Lotan; Alexander Bachmann; Michael Rink; Alberto Briganti; Shahrokh F Shariat
Journal:  World J Urol       Date:  2016-04-29       Impact factor: 4.226

Review 10.  N-cadherin in cancer metastasis, its emerging role in haematological malignancies and potential as a therapeutic target in cancer.

Authors:  Krzysztof Marek Mrozik; Orest William Blaschuk; Chee Man Cheong; Andrew Christopher William Zannettino; Kate Vandyke
Journal:  BMC Cancer       Date:  2018-10-01       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.